-
Li Li meets with secretary for social affairs and culture of Macao SAR
2025-08-06
Li Li, commissioner of the National Medical Products Administration (NMPA), met with a delegation led by O Lam, secretary for social affairs and culture of the Macao Special Administrative Region (SAR), in Beijing on July 24.
-
China-EU exchange on cosmetics regulatory system held in Beijing
2025-07-25
An exchange event on cosmetics regulatory system between China and the European Union (EU) was held in Beijing on July 16. Xu Jinghe, deputy commissioner of China's National Medical Products Administration (NMPA), attended the meeting.
-
Chinese vice-premier calls for boosting basic pharmaceutical research, sci-tech innovation
2025-07-11
Liu, also a member of the Political Bureau of the Communist Party of China Central Committee, visited Peking University's School of Pharmaceutical Sciences to learn about medical research and development, as well as the construction and operations of key laboratories, and listened to opinions from various relevant parties at a symposium.
-
Li Li meets with head of Uzbekistan’s Center for Safety of Pharmaceutical Products
2025-07-03
Li Li, commissioner of China's National Medical Products Administration (NMPA), met with a delegation led by Alisher Temirov, acting director of the Center for the Safety of Pharmaceutical Products of the Ministry of Health of Uzbekistan, in Beijing on June 27.
-
NMPA holds meeting to review QMS in vaccine regulation, pharmaceutical manufacturing inspection
2025-06-16
The National Medical Products Administration (NMPA) held a meeting on June 9 to conduct the 2024 annual review of the quality management system (QMS) in vaccine regulation and pharmaceutical manufacturing inspection.
-
NMPA Announcement on Further Improvement and Optimization of Matters Concerning the Production of Imported Medical Devices in Domestic Enterprises in China (No. 30, 2025)
2025-06-11
To thoroughly implement the decisions of the CPC Central Committee and the State Council on advancing high-level opening-up, fully carry out the requirements of the Opinions of the General Office of the State Council on Comprehensively Deepening the Regulatory Reform of Drugs and Medical Devices to Promote the High-Quality Development of the Pharmaceutical Industry (GBF [2024] No. 53), continuously deepen the reform of medical device regulation, and promote the high-quality development of the medical device industry, the following adjustments and optimizations are hereby made to certain provisions of the Announcement.
